Compare Twilio Inc (TWLO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twilio Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Twilio Inc trades at $289.47 (market cap $42.35B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Twilio Inc is far larger — about 4.2× State Street SPDR S&P Biotech ETF's market cap, and Twilio Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twilio Inc for 56 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TWLO | XBI | |
|---|---|---|
Market Cap | $42.35B | $10.11B |
Volume | 1,862,642 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $301.27 | $169.55 |
52-Week Low | $106.23 | $104.99 |
Typical Hold Time | 56 Days | 38 Days |
Enterprise Value | $40.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twilio (TWLO) trades at $275.77, up 1.01% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company has shown strong revenue growth, reaching $5.07B in 2025, and a significant improvement in net income to $33.83M. Recent news highlights its upcoming inclusion in the S&P 500 index, reflecting increased market recognition and institutional interest.
Outlook is positive with accelerating revenue growth and profitability, supported by AI-driven communication services. Key risks include high valuation multiples and competitive pressures. Analyst consensus is bullish with a 76.92% buy rating, though price targets suggest near-term consolidation potential from current levels.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
